文献速递造血干细胞移植与细胞治疗白血病

急性淋巴细胞白血病中T细胞充足单倍体移植:骨髓与外周血干细胞移植物比较

Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2020-05-11

本研究比较急性淋巴细胞白血病(ALL)患者接受T细胞充足单倍体造血干细胞移植(haplo-HCT)联合移植后环磷酰胺(PTCy)时,骨髓(BM)与外周血(PB)干细胞移植物对结局的影响。共纳入314例ALL患者(BM组157例,PB组157例)。PB组第30天植入累积发生率高于BM组(93% vs 88%,p < 0.01)。多因素分析显示,与BM组相比,PB组无白血病生存(LFS)(HR = 1.43,p = 0.05)、总生存(OS)(HR = 1.59,p = 0.02)和无GVHD无复发生存(GRFS)(HR = 1.42,p = 0.03)均较低。结论:在ALL患者接受PTCy单倍体移植时,使用BM移植物较PB干细胞移植物可获得更好的生存。

要点

  • PB组第30天植入率高于BM组(93% vs 88%,p < 0.01)。
  • PB组与BM组相比,LFS(HR = 1.43,p = 0.05)、OS(HR = 1.59,p = 0.02)、GRFS(HR = 1.42,p = 0.03)均较低。
  • 两组复发率无差异(HR = 1.23,p = 0.41)。

核心结论

  • 在ALL患者接受PTCy单倍体移植时,使用BM移植物较PB干细胞移植物可获得更好的生存。

研究设计与样本

  • 研究纳入314例ALL患者,比较BM移植物(157例)与PB移植物(157例)在haplo-HCT联合PTCy中的结局。

主要发现

  • PB组第30天植入累积发生率高于BM组(93% vs 88%,p < 0.01)。
  • 急性GVHD和慢性GVHD发生率在研究队列间无显著差异。
  • 多因素分析显示,与BM组相比,PB组II-IV级急性GVHD(HR = 1.52,p = 0.07)、慢性GVHD(HR = 1.58,p = 0.05)和非复发死亡(NRM)(HR = 1.66,p = 0.06)有升高趋势。
  • 与BM组相比,PB组LFS较低(HR = 1.43,p = 0.05),OS较低(HR = 1.59,p = 0.02),GRFS较低(HR = 1.42,p = 0.03)。
  • 两组复发率无差异(HR = 1.23,p = 0.41)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ideal stem cell graft source remains unknown in haploidentical haematopietic cell transplantation (haplo-HCT) with posttransplantation cyclophosphamide (PTCy). This study compared outcomes of bone marrow (BM) versus peripheral blood (PB) stem cell graft for haplo-HCT in acute lymphoblastic leukemia (ALL). A total of 314 patients with ALL (BM-157; PB-157) were included in this study. The cumulative incidence of engraftment at day 30 was higher in the PB group compared with BM (93% vs. 88%, p < 0.01). The incidences of acute graft-versus-host disease (GVHD) and chronic GVHD were not significantly different between the study cohorts. In the multivariate analysis, there were tendencies toward a higher incidence of grade II-IV acute GVHD (hazard ratio (HR) = 1.52, p = 0.07), chronic GVHD (HR = 1.58, p = 0.05), and nonrelapse mortality (NRM) (HR = 1.66, p = 0.06) in patients receiving PB versus BM graft, respectively. The use of PB grafts was associated with lower leukemia-free survival (LFS) (HR = 1.43, p = 0.05), overall survival (OS) (HR = 1.59, p = 0.02), and GVHD-free, relapse-free survival (GRFS) (HR = 1.42, p = 0.03) compared with BM grafts. There was no difference in relapse incidence (HR = 1.23, p = 0.41) between the study groups. In conclusion, use of BM graft results in better survival after haplo-HCT with PTCy in patients with ALL, compared with PB stem cell graft.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Nagler A, Dholaria B, Labopin M, et al. Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia. 2020. PMID: 32393841. doi:10.1038/s41375-020-0850-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。